Triglyceride glucose-body mass index as a novel predictor of slow coronary flow phenomenon in patients with ischemia and nonobstructive coronary arteries (INOCA)

BMC Cardiovasc Disord. 2024 Jan 19;24(1):60. doi: 10.1186/s12872-024-03722-4.

Abstract

Background: The triglyceride glucose-body mass index (TyG-BMI index) has been suggested as a novel predictor of insulin resistance. However, its predictive value for slow coronary flow phenomenon (SCFP) in patients with ischemia and nonobstructive coronary arteries (INOCA) remains unclear.

Methods: We consecutively recruited 1625 patients with INOCA from February 2019 to February 2023 and divided them into two groups based on thrombolysis in myocardial infarction (TIMI) frame counts (TFCs): the SCFP group (n = 79) and the control group. A 1:2 age-matched case-control study was then performed. The TyG-BMI index was calculated as ln [plasma triglyceride (mg/dL) × fasting blood glucose (mg/dL)/2] × BMI.

Results: TyG-BMI index in the SCFP group (218.3 ± 25.2 vs 201.0 ± 26.5, P < .001) was significantly higher than in the normal controls. TyG-BMI index also increased with the number of coronary arteries involved in the SCFP. Multivariate logistic regression analysis showed that TyG-BMI, BMI, and TG were independent predictors for SCFP. Receiver operating characteristic (ROC) curve analysis showed that when the TyG-BMI index was above 206.7, the sensitivity and specificity were 88.6% and 68.5%, respectively, with an AUC of 0.809 (95% CI: 0.756-0.863, P = .027). Combined BMI with TG, the TyG-BMI index had a better predictive value for SCFP than BMI and TG (P < .001).

Conclusion: The TyG-BMI index was an independent predictor for SCFP in INOCA patients, and it had a better predictive value than BMI and TG.

Keywords: Ischemia and nonobstructive coronary arteries; Predictors; Slow coronary flow fhenomenon; Triglyceride glucose-body mass index.

MeSH terms

  • Biomarkers
  • Blood Glucose
  • Body Mass Index
  • Case-Control Studies
  • Coronary Vessels
  • Glucose*
  • Humans
  • Ischemia
  • No-Reflow Phenomenon* / diagnostic imaging
  • No-Reflow Phenomenon* / etiology
  • Triglycerides

Substances

  • Glucose
  • Blood Glucose
  • Triglycerides
  • Biomarkers